However, these WDR5 PPI inhibitors, which rely on receptor occupancy pharmacology and target only some but not all WDR5’s oncogenic functions, exert rather modest cancer cell killing effects in general and lack in vivo efficacy (18–31). This evidence concerns the gene WDR5 and cancer.